Table 4.

Summary of recommendations from the European Society of Anesthesiology and Intensive Care (ESAIC), the European Society of Cardiology (ESC), the Canadian Cardiovascular Society Guidelines (CCSG), and the American Heart Association (AHA).

ESAIC/ESC	CCSG	AHA
In patients who have known CVD, CV risk factors	If a patient’s age is ≥65, RCRI ≥ 1 or aged 45–64 with	High-risk individuals (i.e., >65 or >45 with
(including age ≥ 65 years), or symptoms suggestive of CVD, it is recommended to measure hs-cTn before intermediate and high risk NCS, and at 24 h and 48 h afterwards. In patients who have known CVD, CV risk factors (including age ≥ 65 years), or symptoms suggestive of CVD, it should be considered to measure BNP or NT-proBNP before intermediate and high risk NCS.	significant CVD, order BNP or NT-proBNP. AND if positive NT-proBNP ≥ 300 pg/mL or BNP ≥ 92 pg/mL OR BNP or NT-proBNP not available, THEN Measure troponin daily × 48–72 h Not routine hsTn monitoring if proBNP < 300 pg/mL	established CVD or peripheral atherosclerotic), having NCS, have serial hsTn measurements during the first 48–72 h postoperatively while hospitalized. MINS diagnostic criteria should be used to standardize assessment and reporting of ischemic events in clinical practice and future clinical trials

CVD: cardiovascular disease; NCS: noncardiac surgery; RCRI: revised cardiac risk index.